YS Biopharma Reports Unaudited H1 FY24 Financial Results
Ticker: LSBWF · Form: 6-K · Filed: Jan 22, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, biopharma, 6-K
TL;DR
**YS Biopharma just dropped its unaudited H1 FY24 financials, giving us an early peek at their performance.**
AI Summary
YS Biopharma Co., Ltd. (NASDAQ: YS) announced its unaudited consolidated financial results for the first half of fiscal year 2024, which ended on March 31, 2024, via a 6-K filing on January 22, 2024. The filing includes a press release (Exhibit 99.1) detailing these results. This matters to investors because it provides an early look at the company's financial performance for the first half of its fiscal year, offering insights into its operational health and progress in developing vaccines and biologics.
Why It Matters
This filing provides investors with crucial, albeit unaudited, financial data for the first half of YS Biopharma's fiscal year, allowing them to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The financial results are unaudited, meaning they haven't been fully reviewed by an independent auditor, which carries a higher risk of future adjustments compared to audited statements.
Analyst Insight
Investors should review the unaudited financial results for the first half of fiscal year 2024 to understand YS Biopharma's recent performance, but also note that these results are subject to change as they are not yet audited.
Key Players & Entities
- YS Biopharma Co., Ltd. (company) — registrant and global biopharmaceutical company
- Hui Shao (person) — Director and Chief Executive Officer of YS Biopharma
- Dr. David Shao (person) — Director, President, and CEO of YS Biopharma
- January 22, 2024 (date) — date of the 6-K filing and press release
- March 31, 2024 (date) — end date of the first half of fiscal year 2024
FAQ
What is the purpose of YS Biopharma's 6-K filing dated January 22, 2024?
The 6-K filing by YS Biopharma Co., Ltd. on January 22, 2024, is to report its unaudited consolidated financial results for the first half of the fiscal year ended March 31, 2024, as detailed in Exhibit 99.1, a press release.
Who signed the 6-K report on behalf of YS Biopharma and what is their title?
The 6-K report was signed by Hui Shao, who holds the title of Director and Chief Executive Officer of YS Biopharma Co., Ltd., on January 22, 2024.
What is the fiscal year-end for YS Biopharma Co., Ltd.?
YS Biopharma Co., Ltd.'s fiscal year ends on March 31, as indicated by the 'CONFORMED PERIOD OF REPORT: 20240122' and the reference to 'first half of the fiscal year ended March 31, 2024'.
Where are YS Biopharma's principal executive offices located?
YS Biopharma's principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
What is the primary business of YS Biopharma Co., Ltd.?
YS Biopharma Co., Ltd. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2024-01-22 17:10:55
Filing Documents
- ea191942-6k_ysbiopharma.htm (6-K) — 10KB
- ea191942ex99-1_ysbiopharma.htm (EX-99.1) — 205KB
- 0001213900-24-005360.txt ( ) — 217KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YS Biopharma Co., Ltd. Date: January 22 , 2024 By: /s/ Hui Shao Name: Hui Shao Title: Director and Chief Executive Officer 2